Browsing Tag
SEQUOIA-HCM
2 posts
Cytokinetics stock skyrockets 40% as ESC 2025 data positions aficamten to challenge beta-blockers in HCM
Cytokinetics shares surged 40% after new ESC 2025 data showed aficamten's superiority to metoprolol in HCM. Is FDA approval now inevitable?
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…